Open AccessResearch progress in immunotherapy of advanced non-small cell lung cancer
Author(s) -
Xin Lü,
Huaqiu Shi,
Qiuyang Que,
Song Qiu
Publication year - 2021
Publication title -
trends in immunotherapy
Language(s) - English
Resource type - Journals
ISSN - 2573-5985
DOI - 10.24294/ti.v5.i2.1.1367
Subject(s) - nivolumab , medicine , immunotherapy , lung cancer , food and drug administration , oncology , chemotherapy , drug , intensive care medicine , cancer , pharmacology
Non-small cell lung cancer (NSCLC) poses a serious threat to people’s health. Its morbidity and mortality are among the highest among all malignant tumors, and there is an urgent need for more effective new treatment methods. In recent years, NSCLC immunotherapy has made great progress, the first PD-1 inhibitor nivolumab (Nivolumab, O drug) was approved by the US Food and Drug Administration (FDA) in March 2015, applying to the patients who progressed or has received platinum chemotherapy drugs in the past. Immunotherapy of advanced NSCLC has entered a new era. This article reviews the current research progress of NSCLC immunotherapy.